A start-up ketamine clinic needed $5,000,000 of professional liability limits to satisfy a contract. The owner had no prior experience in the field. That combination — novel treatment modality, new venture, inexperienced ownership, high contractual limit — sits at the far edge of what the professional liability market likes to write, and the fact that it got placed at all is a useful case study in how emerging medical risks find insurance.
Ketamine therapy illustrates the emerging-risk problem cleanly. The treatment has legitimate and growing clinical support for depression and chronic pain, but it operates in a regulatory gray zone: FDA-approved as an anesthetic, widely used off-label for psychiatric indications, delivered through clinic models that range from hospital-grade to spa-adjacent. Underwriters pricing professional liability need claims data, and the defining feature of an emerging practice is that the data does not exist. Pricing becomes judgment: the carrier underwrites the protocols, the physician oversight, the screening and consent processes, and the operators themselves.
The contractual limit requirement adds a second layer. A $5M requirement typically originates with a landlord, a health system partner, or a licensing framework, and it is non-negotiable by design — the counterparty is transferring its own perceived risk. For a start-up, the requirement lands before revenue exists, which means the premium is paid from seed capital against a contract the business cannot afford to lose. Structure becomes the tool: a $1M primary professional layer with $4M of excess or umbrella above it is usually how the number is reached, and the excess market’s willingness to sit over a novel primary risk is its own underwriting conversation.
The inexperience problem is handled the way it always is in professional lines: by borrowing credibility. Medical director arrangements, advisory boards, established protocols adopted wholesale from academic programs, and credentialed clinical staff all convert an unknown operator into an underwriteable risk profile. The application is, in effect, an argument that the venture’s novelty is supervised novelty.
The broader pattern repeats across every new corner of medicine — telehealth platforms, med-spas, psychedelic-adjacent therapies, IV hydration. The market insures them all eventually. The gap between “eventually” and “now” is bridged by brokers who know which carriers write the class and by operators willing to build the controls underwriters are really buying.
This article is adapted from Samuel’s original LinkedIn post, “$5M. That was a contract requirement for a start-up Ketamine Clinic”, published April 22, 2026. Read the original post on LinkedIn →